|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
CA1276103C
(en)
|
1984-10-02 |
1990-11-13 |
Fumiaki Taguchi |
Substance-conjugated complement component c1q
|
|
JPS61271455A
(ja)
|
1985-05-28 |
1986-12-01 |
Olympus Optical Co Ltd |
免疫学的分析方法
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
AU663725B2
(en)
|
1991-08-20 |
1995-10-19 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
CA2115811A1
(en)
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
|
ES2249761T3
(es)
|
1993-06-24 |
2006-04-01 |
Advec Inc. |
Vectores de adenovirus para terapia genica.
|
|
AU678064B2
(en)
|
1993-09-01 |
1997-05-15 |
Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis |
Method to reduce myocardial injury during acute myocardial infarction
|
|
SK283703B6
(sk)
|
1993-10-25 |
2003-12-02 |
Canji, Inc. |
Rekombinantný adenovírusový vektor a jeho použitie
|
|
KR100551104B1
(ko)
|
1994-12-09 |
2006-02-09 |
임페리얼 컬리지 이노베이션스 리미티드 |
유전자의 동정
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
WO1998017815A1
(en)
|
1996-10-17 |
1998-04-30 |
Oxford Biomedica (Uk) Limited |
Retroviral vectors
|
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB9622500D0
(en)
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
CN101298481A
(zh)
|
1998-02-20 |
2008-11-05 |
吉宁特有限公司 |
补体活化的抑制剂
|
|
US6103526A
(en)
|
1998-10-08 |
2000-08-15 |
Protein Sciences Corporation |
Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
|
|
JP2003529536A
(ja)
|
1999-02-09 |
2003-10-07 |
３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド |
Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物
|
|
WO2000064327A2
(en)
|
1999-04-26 |
2000-11-02 |
Duke University |
Inhibition of complement action
|
|
WO2001013945A1
(en)
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
|
WO2001053825A1
(en)
|
2000-01-19 |
2001-07-26 |
Biotransplant, Inc. |
Swine defective for transmission of porcine endogenous retrovirus and uses thereof
|
|
DE122011000002I1
(de)
|
2000-01-31 |
2011-05-05 |
Pharming Intellectual Pty Bv |
Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
|
|
US6998468B2
(en)
|
2000-03-23 |
2006-02-14 |
Tanox, Inc. |
Anti-C2/C2a inhibitors of complement activation
|
|
AU2001282857A1
(en)
|
2000-06-21 |
2002-01-02 |
Zymogenetics Inc. |
Peptide and polypeptide inhibitors of complement c1s
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
|
WO2003009803A2
(en)
|
2001-07-26 |
2003-02-06 |
Alexion Pharmaceuticals Inc. |
Method of improving cognitive function
|
|
WO2003042361A2
(en)
|
2001-11-09 |
2003-05-22 |
Government Of The United States Of America, Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
|
NZ533692A
(en)
|
2002-01-11 |
2006-09-29 |
Gtc Biotherapeutics Inc |
Improved methods for the fusion and activation of reconstructed embryos for use in nuclear transfer procedures in non-human mammals
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
AU2003270330B2
(en)
|
2002-09-06 |
2009-07-30 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component C5
|
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
|
US9715692B1
(en)
|
2003-04-11 |
2017-07-25 |
Facebook, Inc. |
System for managing bids for pay-per-click search engines
|
|
CN1787741B
(zh)
|
2003-05-15 |
2011-08-17 |
唐纳士公司 |
用于预防和治疗败血症的方法与组合物
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
JP2007512846A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
CN1942483B
(zh)
*
|
2004-04-13 |
2012-09-26 |
弗·哈夫曼-拉罗切有限公司 |
抗p型选凝素抗体
|
|
PL2465534T3
(pl)
|
2004-06-10 |
2017-08-31 |
Omeros Corporation |
Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US20060018896A1
(en)
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
|
US8951522B2
(en)
|
2011-04-08 |
2015-02-10 |
University Of Leicester |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2005313971B2
(en)
|
2004-12-08 |
2011-10-13 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
|
AU2006227778A1
(en)
|
2005-03-16 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
|
|
US8163881B2
(en)
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
|
EP1893227A2
(en)
|
2005-06-06 |
2008-03-05 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
|
JP5193600B2
(ja)
|
2005-07-05 |
2013-05-08 |
株式会社カネカ |
メタクリル系樹脂組成物
|
|
US8124076B2
(en)
|
2005-08-18 |
2012-02-28 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against β-amyloid peptide
|
|
WO2007047995A2
(en)
|
2005-10-21 |
2007-04-26 |
Catalyst Biosciences, Inc. |
Modified proteases that inhibit complement activation
|
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
US8148330B2
(en)
|
2005-12-09 |
2012-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
SI2380587T1
(en)
|
2005-12-21 |
2018-03-30 |
Pharming Intellectual Property B.V. |
Use of a C1 inhibitor to prevent ischemic reperfusion injury
|
|
FR2897868B1
(fr)
*
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
CA3009846C
(en)
|
2006-03-08 |
2021-08-31 |
David Epstein |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
|
AR060040A1
(es)
|
2006-03-21 |
2008-05-21 |
Genentech Inc |
Antagonistas de vefg y de alfa5 beta 1
|
|
KR101589259B1
(ko)
|
2006-06-21 |
2016-02-01 |
유니큐어 아이피 비.브이. |
곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터
|
|
US9388235B2
(en)
|
2006-09-05 |
2016-07-12 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
NZ576195A
(en)
|
2006-10-10 |
2012-04-27 |
Az Univ Amsterdam |
Complement inhibition for improved nerve regeneration
|
|
US7858752B2
(en)
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
|
WO2008074227A1
(en)
|
2006-12-19 |
2008-06-26 |
Versitech Limited |
Synthetic ion channels
|
|
WO2008097525A2
(en)
|
2007-02-05 |
2008-08-14 |
Potentia Pharmaceuticals, Inc. |
Local complement inhibition for treatment of complement-mediated disorders
|
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CA2693852C
(en)
|
2007-08-03 |
2016-11-29 |
Genentech, Inc. |
Humanized anti-fgf19 antagonists and methods using same
|
|
US7788398B2
(en)
*
|
2007-08-08 |
2010-08-31 |
Swarmcast, Inc. |
Media player plug-in installation techniques
|
|
PL2808343T3
(pl)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Warianty Fc ze zmienionym wiązaniem do FcRn
|
|
WO2009121065A2
(en)
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
JP5739326B2
(ja)
|
2008-04-25 |
2015-06-24 |
ザイモジェネティクス， インコーポレイテッド |
Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
|
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
WO2009151634A1
(en)
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
WO2010047830A2
(en)
|
2008-10-24 |
2010-04-29 |
The Scripps Research Institute |
Agents for hcv treatment
|
|
HUE061548T2
(hu)
|
2008-11-10 |
2023-07-28 |
Alexion Pharma Inc |
Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
|
|
WO2010065425A1
(en)
|
2008-12-01 |
2010-06-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for detection of complement fixing antibodies
|
|
WO2010063785A2
(en)
|
2008-12-03 |
2010-06-10 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US20110002931A1
(en)
|
2009-06-23 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
AU2010306581B2
(en)
|
2009-10-16 |
2015-03-19 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
|
|
JP5851391B2
(ja)
|
2010-02-16 |
2016-02-03 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
|
NZ602219A
(en)
|
2010-03-01 |
2014-10-31 |
Alexion Pharma Inc |
Methods and compositions for treating degos’ disease
|
|
DK2826860T3
(en)
|
2010-04-23 |
2018-12-03 |
Univ Massachusetts |
CNS targeting AAV vectors and methods for their use
|
|
EA028899B1
(ru)
|
2010-04-30 |
2018-01-31 |
Алексион Фармасьютикалз, Инк. |
АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
|
|
WO2011146514A2
(en)
|
2010-05-17 |
2011-11-24 |
The Board Of Regents Of The University Of Texas System |
Rapid isolation of monoclonal antibodies from animals
|
|
CN103249432A
(zh)
|
2010-06-22 |
2013-08-14 |
科罗拉多大学董事会,法人团体 |
补体成分3的C3d片段的抗体
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
|
MX379481B
(es)
|
2010-12-06 |
2025-03-11 |
Seagen Inc |
Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer
|
|
JP6147670B2
(ja)
|
2010-12-22 |
2017-06-14 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
改善された半減期を有する修飾された抗体
|
|
EP3725811A3
(en)
|
2011-05-04 |
2021-01-27 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement activation
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
US9452203B2
(en)
|
2011-12-22 |
2016-09-27 |
Csl Behring Gmbh |
Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
|
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Ｉｌ−２８ｂの分析方法
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
CN104870475B
(zh)
|
2012-10-25 |
2019-11-08 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
|
CA2889197A1
(en)
|
2012-11-02 |
2014-05-08 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
|
EP2975055A4
(en)
*
|
2013-01-31 |
2016-11-02 |
Univ Seoul Nat R & Db Found |
C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
US20160090425A1
(en)
|
2013-05-15 |
2016-03-31 |
Annexon, Inc. |
Anti-complement factor c1s antibodies and uses thereof
|
|
US9944717B2
(en)
|
2013-05-23 |
2018-04-17 |
Broteio Pharma B.V. |
Binding molecules that bind human complement factor C2 and uses thereof
|
|
BR112016000106B1
(pt)
*
|
2013-07-09 |
2023-11-21 |
Annexon, Inc. |
Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
|
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
|
BR112017007393A2
(pt)
|
2014-10-18 |
2017-12-19 |
Pfizer |
composições de anticorpo anti-il-7r
|
|
PT3280440T
(pt)
*
|
2015-04-06 |
2023-02-14 |
Bioverativ Usa Inc |
Anticorpos anti-c1s humanizados e métodos de utilização destes
|
|
WO2016210172A1
(en)
|
2015-06-26 |
2016-12-29 |
True North Therapeutics, Inc. |
Methods of treating autoimmune and alloimmune disorders
|
|
CN116554320A
(zh)
|
2016-10-12 |
2023-08-08 |
美国比奥维拉迪维股份有限公司 |
抗C1s抗体及其使用方法
|
|
BR112019018950A2
(pt)
|
2017-03-14 |
2020-04-22 |
Bioverativ Usa Inc. |
métodos para tratamento de doenças e distúrbios mediados por complemento
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
KR20200143459A
(ko)
|
2018-04-13 |
2020-12-23 |
추가이 세이야쿠 가부시키가이샤 |
항-보체 성분 항체 및 사용 방법
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
MX2023001492A
(es)
|
2020-08-06 |
2023-03-08 |
Bioverativ Usa Inc |
Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.
|
|
WO2022212645A1
(en)
|
2021-03-31 |
2022-10-06 |
Bioverativ Usa Inc. |
Reducing surgery-associated hemolysis in cold agglutinin disease patients
|
|
JP2025520434A
(ja)
|
2022-06-15 |
2025-07-03 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
抗補体Ｃ１ｓ抗体製剤
|
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|